Across the recent three months, 4 analysts have shared their insights on Editas Medicine (NASDAQ:EDIT), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 0 | 3 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 0 | 2 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Editas Medicine, revealing an average target of $9.5, a high estimate of $15.00, and a low estimate of $7.00. Highlighting a 32.14% decrease, the current average has fallen from the previous average price target of $14.00.
Investigating Analyst Ratings: An Elaborate Study
The standing of Editas Medicine...
Login or create a forever free account to read this news
Sign up/Log in